These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18397710)

  • 21. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
    Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
    Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
    [No Abstract]   [Full Text] [Related]  

  • 22. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hepatitis C in renal transplantation candidates: a single-center experience.
    Werner T; Aqel B; Balan V; Byrne T; Carey E; Douglas D; Heilman RL; Rakela J; Mekeel K; Reddy K; Vargas HE
    Transplantation; 2010 Aug; 90(4):407-11. PubMed ID: 20571469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of infection due to hepatitis C virus in haemodialysis].
    Hidalgo-Collazos P; Marín-Ventura L; Sánchez R; García-López L; Criado-Illana MT
    Nefrologia; 2014; 34(1):132-3. PubMed ID: 24463875
    [No Abstract]   [Full Text] [Related]  

  • 28. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon alpha-2b in patients with acute hepatitis C.
    Mukhopadhyay A
    Natl Med J India; 2006; 19(4):201-2. PubMed ID: 17100108
    [No Abstract]   [Full Text] [Related]  

  • 33. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of hepatitis C in special populations.
    Ramamurthy M; Muir AJ
    Clin Liver Dis; 2006 Nov; 10(4):851-65. PubMed ID: 17164121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    J Med Virol; 2010 May; 82(5):768-75. PubMed ID: 20336712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
    Babatin M; Schindel L; Burak KW
    Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis.
    Sugiura T; Yamada T; Kimpara Y; Fujita N; Goto K; Koyama N
    Pediatr Nephrol; 2009 Jan; 24(1):199-202. PubMed ID: 18696119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.
    Amarapurkar DN; Patel ND; Kirpalani AL
    Trop Gastroenterol; 2007; 28(1):16-8. PubMed ID: 17896604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.